Pathogen-Associated Molecular Pattern in Cancer Immunotherapy

2008 ◽  
Vol 28 (2) ◽  
pp. 95-107 ◽  
Author(s):  
Uwe Hobohm ◽  
John L. Stanford ◽  
John M. Grange
2013 ◽  
Vol 64 (12) ◽  
pp. 3615-3625 ◽  
Author(s):  
Mathieu Larroque ◽  
Elodie Belmas ◽  
Thomas Martinez ◽  
Sophie Vergnes ◽  
Nathalie Ladouce ◽  
...  

2004 ◽  
Vol 82 (6) ◽  
pp. 603-610 ◽  
Author(s):  
Oliver Pérez ◽  
Gustavo Bracho ◽  
Miriam Lastre ◽  
Nestor Mora ◽  
Judith Del Campo ◽  
...  

2021 ◽  
Vol 5 (5) ◽  
pp. 1523-1534
Author(s):  
Johan Courjon ◽  
Océane Dufies ◽  
Alexandre Robert ◽  
Laurent Bailly ◽  
Cédric Torre ◽  
...  

Abstract Dysregulated immune response is the key factor leading to unfavorable coronavirus disease 2019 (COVID-19) outcome. Depending on the pathogen-associated molecular pattern, the NLRP3 inflammasome can play a crucial role during innate immunity activation. To date, studies describing the NLRP3 response during severe acute respiratory syndrome coronavirus 2 infection in patients are lacking. We prospectively monitored caspase-1 activation levels in peripheral myeloid cells from healthy donors and patients with mild to critical COVID-19. The caspase-1 activation potential in response to NLRP3 inflammasome stimulation was opposed between nonclassical monocytes and CD66b+CD16dim granulocytes in severe and critical COVID-19 patients. Unexpectedly, the CD66b+CD16dim granulocytes had decreased nigericin-triggered caspase-1 activation potential associated with an increased percentage of NLRP3 inflammasome impaired immature neutrophils and a loss of eosinophils in the blood. In patients who recovered from COVID-19, nigericin-triggered caspase-1 activation potential in CD66b+CD16dim cells was restored and the proportion of immature neutrophils was similar to control. Here, we reveal that NLRP3 inflammasome activation potential differs among myeloid cells and could be used as a biomarker of a COVID-19 patient’s evolution. This assay could be a useful tool to predict patient outcome. This trial was registered at www.clinicaltrials.gov as #NCT04385017.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Elena Kudryashova ◽  
Pratibha C. Koneru ◽  
Mamuka Kvaratskhelia ◽  
Adam A. Strömstedt ◽  
Wuyuan Lu ◽  
...  

2020 ◽  
Vol 21 (3) ◽  
pp. 706 ◽  
Author(s):  
Yangyang Luo ◽  
Qingyang Wang ◽  
Ru Bai ◽  
Ruixiang Li ◽  
Lu Chen ◽  
...  

In the current study, we identified a transcription factor, MYB14, from Chinese wild grape, Vitis quinquangularis-Pingyi (V. quinquangularis-PY), which could enhance the main stilbene contents and expression of stilbene biosynthesis genes (StSy/RS) by overexpression of VqMYB14. The promoter of VqMYB14 (pVqMYB14) was shown to be induced as part of both basal immunity (also called pathogen-associated molecular pattern (PAMP)-triggered immunity, PTI) and effector-triggered immunity (ETI), triggered by the elicitors flg22 and harpin, respectively. This was demonstrated by expression of pVqMYB14 in Nicotiana benthamiana and Vitis. We identified sequence differences, notably an 11 bp segment in pVqMYB14 that is important for the PTI/ETI, and particularly for the harpin-induced ETI response. In addition, we showed that activation of the MYB14 promoter correlates with differences in the expression of MYB14 and stilbene pattern induced by flg22 and harpin. An experimental model of upstream signaling in V. quinquangularis-PY is presented, where early defense responses triggered by flg22 and harpin partially overlap, but where the timing and levels differ. This translates into a qualitative difference with respect to patterns of stilbene accumulation.


Sign in / Sign up

Export Citation Format

Share Document